| CPC C07F 5/025 (2013.01) | 20 Claims |
|
1. A method of treating a disease in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I):
 or a pharmaceutically acceptable salt thereof, wherein:
W is —O—P-Q-C(R8a)═C(R8b)(R8c), —N(R′)—P-Q-C(R8a)═C(R8b)(R8c), or a group of formula
 A1 is hydrogen, hydroxy, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or —S(═O)2-alkyl, wherein said alkyl of said —S(═O)2-alkyl is optionally substituted;
R′ is H or optionally substituted alkyl;
each R1 is H or optionally substituted alkyl;
P is -alkyl-, -alkyl-O-alkyl-, -alkyl-N(R)—, -alkyl-aryl-N(R)—, -alkyl-N(R)-aryl-N(R)—, -alkyl-O-aryl-N(R)—, -alkyl-aryl-alkyl-N(R)—, -alkyl-heteroaryl-N(R)—, -alkyl-cycloalkyl-N(R)—, -alkyl-O-cycloalkyl-N(R)—, -alkyl-N(R)-cycloalkyl-N(R)—, -alkyl-O-alkyl-N(R)—, -alkyl-N(R)-alkyl-N(R)—,
 or
 wherein each instance of alkyl, aryl, heteroaryl, and cycloalkyl is optionally substituted;
Z and Z1 are independently a covalent bond, -alkyl-, -alkyl-O—, -alkyl-N(R)—, or -alkyl-O-alkyl-, wherein each instance of alkyl is optionally substituted;
ring A with the ring nitrogen atom shown is an optionally substituted saturated mono- or multicyclic 4 to 10 membered heterocyclyl;
ring J with the ring nitrogen atom and ring Y1 atom shown is an optionally substituted saturated 4 to 10 membered heterocyclyl;
Y1 is C or N;
Z2 is a covalent bond or N(R);
each R is independently hydrogen or optionally substituted alkyl;
Q is —C(═O)— or —S(═O)2—;
each R8a independently is hydrogen, halogen, or cyano;
each R8b independently is hydrogen or optionally substituted alkyl; or
each R8a and R8b independently are taken together to form a bond; and
each R8c independently is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
Rb1 is optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, or optionally substituted heterocyclyl;
Rb2 and Rb3 are independently hydrogen or optionally substituted C1-6 alkyl; or
Rb2 and Rb3 together with the boron atom to which they are shown attached form an optionally substituted cyclic boronic ester having 2 to 20 carbons, and optionally containing one or two additional cyclic heteroatoms chosen from N, O and S; and
m and n are independently 0 or 1;
provided that when W is —O—P-Q-C(R8a)═C(R8b)(R8c), or a group of formula
 wherein m and n are each 0, then P is not -alkyl-N(R)—, -alkyl-(C3-C6) cycloalkyl-N(R)—, alkyl-O-alkyl-N(R)—, or
 wherein each instance of alkyl, and cycloalkyl is optionally substituted, ring A with the ring nitrogen atom as shown is an optionally substituted saturated monocyclic five- to seven-membered heterocyclyl with only the one nitrogen shown as the ring heteroatom, and wherein Z is connected to ring A at a carbon atom adjacent to the ring nitrogen atom; and
provided that when W is —O—P-Q-C(R8a)═C(R8b)(R8c), or a group of formula
 wherein m and n are each 0, and P is
 wherein Y1 in ring J is nitrogen, then Z2 is a covalent bond,
wherein the disease is chosen from lupus, rheumatoid arthritis, scleroderma, ankylosing spondylitis, Duchene muscular dystrophy (DMD), Becker muscular dystrophy (BMD), idiopathic inflammatory myopathies (IIMs), polymyositis, sporadic inclusion body myositis, dermatomyositis, immune-mediated necrotizing myopathies (IMNM), psoriasis, multiple sclerosis, inflammatory bowel disease, Behçet's disease, ulcerative colitis, Crohn's disease, Sjogren's Syndrome, bronchitis, conjunctivitis, pancreatitis, cholecystitis, bronchiectasis, aortic valve stenosis, restenosis, psoriasis, arthritis, fibrosis, infection, ischemia, cardiovascular disease, hepatitis, cirrhosis, steatohepatitis, liver inflammation, Alzheimer's Disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease, body myositis, myofibrilar myopathy, GVHD, and multiple myeloma.
|